Eli Lilly and Company

David Bleakman

Paul Leslie Ornstein

Stephen Richard Baker

David Lodge

Dennis Michael Zimmerman

Richard L Simon

Hamideh Zarrinmayeh

Sandra Ann Filla

Edward C R Smith

David R Helton

Kirk Willis Johnson

Macklin Brian Arnold

Ken Matsumoto

Thomas John Bleisch

Ana Maria Escribano

Buddy Eugene Cantrell

Joseph P Tizzano

Carlos Lamas-Peteira

Tracey E McKennon

Iyengar Smriti

Use of compounds of the formula (I) where A, E, R, R, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.

Naphtalene derivatives and their pharmaceutical use

The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR receptor antagonist. The present invention further provides novel compounds functional as selective iGluR receptor antagonists as well as compositions and formulations comprising said selective iGluR receptor antagonists.

Selective iGluR5 receptor antagonists for the treatment of migraine

Sulphonamide derivatives

A hippocampal GluR5 receptor modulator, 2-amino-3-(3 2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid (ATPA) is useful in methods of measuring the binding affinity of chemical compounds to GluR5 receptors.

Assay for evaluating the affinity of compounds to the glutamate GluR5 receptor

Antagonists selective for the GluR5 receptor are useful for the treatment of pain. Also disclosed are novel decahydroisoquinoline derivatives which are selective GluR5 receptor antagonists.

Pharmacological agents

Growing community of inventors

Zionsville, IN, United States of America

David Bleakman